Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T22:48:41.129Z.
Calculation as of: 2026-10-06T22:48:41.129Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76451fd983189bd376b55241b8a4b850ffcaa8def2b2c0e687122d8ae3ae7442
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$72.83M
EV/FCF Ratio
N/A
TTM Avg
1223.62x
3Y Avg
1223.62x
5Y Avg
1223.62x
Market Cap
$69.61M
EV/FCF Ratio
N/A
TTM Avg
16.52x
3Y Avg
23.77x
5Y Avg
35.86x
Market Cap
$68.90M
EV/FCF Ratio
1.03x
TTM Avg
6.09x
3Y Avg
5.75x
5Y Avg
4.59x
Market Cap
$75.95M
EV/FCF Ratio
14.24x
TTM Avg
14.85x
3Y Avg
42.42x
5Y Avg
42.42x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | $72.32M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | N/A | 1223.62x | 1223.62x | 1223.62x |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | N/A | N/A | N/A | N/A |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | N/A | 16.52x | 23.77x | 35.86x |
| Pulmonx Corporation (LUNG)vs › | $75.18M | N/A | N/A | N/A | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 1.03x | 6.09x | 5.75x | 4.59x |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | 14.24x | 14.85x | 42.42x | 42.42x |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
